Samsung Biologics (207940) Q1 2025 earnings summary

Executive summary

• Q1 2025 saw robust earnings, with consolidated revenue at KRW 1,298.3B and operating profit at KRW 486.7B (OPM 37.5%), driven by Plant 4 ramp-up, favorable FX, and strong CDMO performance.

• Operates in two main segments: CDMO and biopharmaceutical development/commercialization, with global reach and diversified product portfolio.

• Major business expansion included ADC facility operations, Plant 5 completion, and a record $1.4B CMO contract with an EU-based pharma.

• Major investments include completion of a new ADC plant and ongoing expansion at the second Bio Campus, with a total planned investment of KRW 7.5 trillion by 2032.

• Biosimilar launches and regulatory approvals in the US and EU supported segment growth.

Financial highlights

• Consolidated revenue grew +37% year-over-year, with Plant 4 and biosimilar sales as key drivers.

• Q1 2025 revenue: KRW 1,298.3B; operating income: KRW 486.7B; net income: KRW 375.6B.

• Biologics segment revenue up +49% YoY to KRW 1,000B; operating profit up +85% YoY to KRW 430B (OPM 43.0%).

• Bioepis segment revenue up +43% YoY to KRW 401B; operating profit up +236% YoY to KRW 128B (OPM 31.9%).

• EBITDA margin improved to 50.1% from 38.5% YoY.

Outlook and guidance

• Full-year consolidated revenue growth guidance remains at +20–25%.

• Biopharma market expected to grow at 9.4% CAGR through 2030; CDMO market forecasted to grow at 15% CAGR through 2029.

• Company plans to expand into mRNA, ADC, and cell/gene therapy, with new facilities and strategic investments in global markets.

• Sustained biosimilar demand expected to drive Bioepis product sales growth of around 20% for 2025.

• Dividend policy targets payout of ~10% of annual FCF, with review of policy planned in 2025.